Retatrutide 10mgRetatrutide 10mg
An investigational triple-hormone peptide, considered only after a full clinician consultation.
Answer a short online consultation. A clinician reviews it, and you only pay if treatment is approved. Dispensed by our licensed facility.
What it is
Retatrutide is a laboratory-made peptide designed to act on three hormone receptors at once: GLP-1, GIP and glucagon. These receptors play roles in appetite signalling, blood sugar handling and energy use. It belongs to the same broad family as other incretin-based peptides but is the first "triple agonist" to reach late-stage trials. It is not yet a licensed medicine in any country.
Why people ask about it
People usually ask about Retatrutide after reading about trial results in metabolic health and body composition, or because they want to discuss whether a newer option is appropriate for them. A consultation lets a clinician look at your full history before any decision is made.
What the science says
Phase 2 trial results have been published in peer-reviewed journals, and larger Phase 3 trials are ongoing. Because trials are still running, long-term safety and effectiveness are not yet fully known. Trial results describe groups of participants under close supervision and do not predict what will happen for any one person.
Is it right for me?
Retatrutide may not be suitable if you are pregnant, planning pregnancy or breastfeeding; have a personal or family history of medullary thyroid cancer or MEN2; have had pancreatitis; have significant gallbladder, kidney or digestive problems; have type 1 diabetes; or take medicines that affect blood sugar. Your clinician will review your full medical history and may ask for recent blood tests.
How Welcuren works
Complete a short online consultation about your health and goals.
A clinician reviews your answers, may ask follow-up questions, and decides whether this treatment is appropriate for you.
You only pay once treatment is approved. Our licensed facility then dispatches it with full instructions, on tracked global delivery.
Safety
Reported side effects in trials include nausea, vomiting, diarrhoea, constipation, reduced appetite and an increased heart rate. As an investigational product, rarer or longer-term effects may not yet be known. Never adjust or start any peptide without clinician guidance, and seek urgent care for severe abdominal pain or signs of an allergic reaction.
Questions
Is Retatrutide a licensed medicine?
No. It is still in clinical trials and has not been licensed anywhere yet. A clinician will discuss what this means for you before any decision.
How is it different from other incretin peptides?
It acts on three receptors (GLP-1, GIP and glucagon) rather than one or two.
Will a clinician always approve it?
No. Every request is assessed individually and may be declined or another option suggested.
Do I need blood tests first?
Your clinician may ask for recent results, particularly for blood sugar, kidney and liver function.
This information is educational and not a substitute for advice from your clinician. Prescription treatments are only supplied after a clinical consultation.
Often considered together
Many clients start with a blood test so their clinician has a full picture.
5-Amino-1MQ5-Amino-1MQ
A small-molecule NNMT inhibitor, not a peptide, with metabolic findings chiefly from cells and mice.
L-CarnitineL-Carnitine
A naturally occurring nutrient involved in mitochondrial fatty-acid transport, with benefits dependent on the clinical setting.